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Abstract
Aim: In chronic myeloid leukemia (CML), the impact of MBCR-ABL1 major transcript type on disease phenotype and
response to treatment still controversial to date. This work aims to study the inﬂuence of Mb3a2 and Mb2a2 transcripts
on clinico-biological parameters and the molecular response in patients with chronic phase chronic myeloid leukemia
(CP-CML) treated with Imatinib as frontline therapy.
Methods: This is six years prospective study started in March 1 st, 2013. 67 patients with newly CP-CML were treated by
Imatinib as frontline therapy. Clinical and biological characteristics disease were collected for all patients. Molecular
typing was performed by multiplex RT-PCR and quantiﬁcation of transcripts by real-time quantitative PCR (qRT-PCR).
The cumulative incidence of deep molecular response (DMR) was estimated by the Kaplan-Meier method. The comparison was made using the parametric Log-Rank test. A value of P ≤ 0.05 is considered signiﬁcant.
Results: 61% of patients expressed b3a2, 35.82% b2a2 and 2.98% expressed a rare transcript of type e19a2. At diagnosis,
the b2a2 type had a higher level of expression than that of b3a2 (67.92 vs 53.79%; P ¼ 0.03). This insigniﬁcant difference
between the two transcript subgroups was also observed for rates below 1% at 6 months (54 vs 39; P ¼ 0.26) and below
0.1% (54 vs 44 %; P ¼ 0.50), (77 vs 50%; P ¼ 0.09) and (81 vs 78 %; P ¼ 0.52) at 12, 18 and 24 months respectively. The two
types of transcript had almost the same kinetics. Nevertheless, the absolute value of the BCR-ABL1/ABL ratio decrease
was faster in the group of patients expressing b3a2, than in those expressing b2a2. At 18 months post IM therapy, patients with a b3a2 transcript have a trend of better MMR that those with b2a2 (77 vs 50%; P ¼ 0.09). The DMR was not
signiﬁcantly different between two groups at 24 months (50 vs 32%; P ¼ 0.20) and 36 months (75 vs 70%; P ¼ 0.54)
respectively. The cumulative probability of achieving MRD at 5 years was higher in patients with b3a2 type but not
statistically signiﬁcant; (85 vs. 68%; P ¼ 0.17).
Conclusion: Patients with b3a2 transcript may be associated with a better response to Imatinib therapy.
Keywords: BCR-ABL1 transcript, Chronic myeloid leukemia, Imatinib therapy, Major molecular response, qRT-PCR

1. Introduction

I

n the context of chronic myeloid leukemia (CML),
b3a2 (e14a2) or b2a2 (e13a2) transcripts are found

in more than 95% of cases. Rarely, the break points
interrupting the BCR and ABL1 genes can be in
alternative regions leading to very rare and atypical
transcripts: e8a2, e6a2, e19a2, e1a3, b2a3, b3a3, and
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e1a2 [1]. The p210BCR-ABL1 chimeric protein encoded
by the BCR-ABL1 fusion gene became the target of
tyrosine kinase inhibitors, with imatinib (IM) as the
ﬁrst-line therapy. This improved the overall survival
of patients with CML which reached that of the
general population [2]. Many studies investigated
the inﬂuence of major transcripts types on the
phenotype of disease and the response to treatment.
However, the results of these studies remain
controversial. The aim of this paper is to examine
the inﬂuence of Mb3a2 and Mb2a2 transcripts on
clinical and biological parameters and the molecular
response in patients with chronic phase CML (CPCML) treated by IM as frontline therapy.
This is a 6-year (2013e2019) prospective, monocentric study, involving 67 patients with newly
diagnosed CP-CML and treated by IM as frontline
therapy. The qualitative research of the BCR-ABL1
transcript was performed by reverse transcriptase
polymerase chain reaction (PCR) multiplex technique using the Seeplex Leukemia BCR/ABL kit
(Seegene, Seoul, Korea). The BCR-ABL1 transcript
levels were measured by real-time quantitative PCR
in peripheral blood samples using a Rotor-Gene
analyzer (Qiagen) with a standardized kit (Ipsogen
kit (Qiagen) BCR-ABL1 Mbcr IS-MMR; R
ef 670823)
according to the European Leukemia Net (ELN)
recommendations [3]. The major molecular
response (MMR) was deﬁned by a reduction of
more than 3log10 (ratio  0.1%) of the expression
level of BCR-ABL1. Crosstabs and Student t test
were performed for the comparison of two averages.
Cumulative incidence of deep molecular response
(DMR) was estimated by the KaplaneMeier method
and log rank test using SPSS software version 20.0
(SPSS Inc., Chicago, IL, USA). A value of p  0.05
was considered signiﬁcant.
Among the 67 patients, 41 (61%) patients
expressed b3a2, 24 (35.82%) patients expressed b2a2,
and two (2.98%) patients expressed a rare transcript
type e19a2. The comparative groups involved 65
patients with major transcripts b3a2 and b2a2,
including 32 (49%) men and 33 (51%) women with a
sex ratio F/M of 1.04. Mean age was 46 ± 13.85
(19e78) years. Epidemiological and clinical characteristics according to the two transcript types of our
series are summarized in Table 1. The median
follow-up duration was 36 (6e72) months. At diagnosis, the median BCR-ABL1/ABL1 ratio was
signiﬁcantly higher in the b2a2 transcript than in
b3a2 transcript (67.92% vs. 53.79%; p ¼ .03) (Table 2).
Furthermore, 64% of patients expressing b3a2 have
a 3-month rate less than 10% compared with 54% of
patients expressing b2a2 ( p ¼ .43). This insigniﬁcant
difference between the two transcript subgroups

Table 1. Baseline Characteristics of Patients with Chronic Myeloid
Leukemia by Type of Major Transcript.
Characteristic

P

Type of transcript

b3a2

b2a2

Patients, n (%)
Age, yr (range)

41(63)
51 (19e78)

24 (37)
46 (20e77)

0.076
0.49

Sex, n (%)
Men
Women

17 (53)
15 (47)

24 (73)
09 (27)

0.98
0.044

Sokal risk score, n (%)
Low
Intermediate
High

10 (24.5)
21(51)
10 (24.5)

7 (29)
8(33.5)
8 (37.5)

0.73
0.65
0.90

EUTOS score, n (%)
Low
High

36 (88)
5 (12)

17 (71)
7 (29)

0.99
0.99

351
11.6
507

0.086
0.78
0.61

Blood cell count, Median
171
WBC, 109/L
Hemoglobin, g/L
10.5
Platelets, 109/L
458

Note. EUTOS ¼ European Treatment and Outcome Study;
n ¼ number; WBC ¼ white blood cell count.

was also observed for rates below 1% at 6 months
(54% vs. 39%; p ¼ .26) and below 0.1% (54% vs. 44%;
p ¼ .50), (77% vs. 50%; p ¼ .09), and (81% vs. 78%;
p ¼ .52) at 12, 18, and 24 months, respectively. The
two types of transcript had almost the same kinetics.
Nevertheless, the absolute value of the BCR-ABL1/
ABL ratio decrease was faster in patients expressing
b3a2 than in those expressing b2a2 (Fig. 1).
The frequency of patients who achieved MMR
increased to 51%, 68%, and 80%, at 12, 18, and
24 months, respectively, with median time to obtain
of 12 months. The frequency of DMR decreased
from 43% to 73% between 24 and 36 months. At
18 months post IM therapy, patients with a b3a2
transcript had a trend of better MMR that those with
a b2a2 transcript (77% vs. 50%; p ¼ .09). DMR was
not signiﬁcantly different between two groups at
24 months (50% vs. 32%; p ¼ .20) and 36 months
(75% vs. 70%; p ¼ .54; Fig. 2). The cumulative
probability of achieving DMR at 5 years was higher
in patients with b3a2 but not statistically signiﬁcant
(85% vs. 68%; p ¼ .17; Fig. 3).
In this paper, we studied the clinical and biological characteristics, the MMR and MRD obtained in
each type of major transcript in patients with newly
diagnosed CP-CML and treated frontline with IM.
The major transcript was the most common with an
incidence of molecular isoform b3a2 higher than
that of b2a2. Several study groups reported different
frequencies of major transcripts b3a2 and b2a2. In a
meta-analysis study, 22 (85%) out of 26 reviewed
articles had a high incidence of the b3a2 transcript,
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Table 2. BCR-ABL1 ratio at diagnosis.
Ratio BCR-ABL1
Ratio Mb3a2
Ratio Mb2a2

Effective

Mean

Median

Standard deviation

Range

p

65
41
24

59
53.79
67.92

60.00
51.00
77.00

25.62
26.16
24.37

14.00e98.00
14.00e97.00
21.00e98.00

NA
0.03

Fig. 1. Decrease in the BCR-ABL1/ABL1 ratio depending on the type of
rearrangement.

Fig. 3. Cumulative incidence of DMR stratiﬁed according to the type of
major transcript. Note. DMR ¼ deep molecular response.

Fig. 2. Proportion of patients with MMR and DMR depending on the
type of major transcript. Note. DMR ¼ deep molecular response;
MMR ¼ major molecular; M ¼ months.

whereas the other articles had a high incidence of
the b2a2 transcript [4]. In a series of 45,503 patients
with newly diagnosed CML reported from 45
countries, the proportion of b2a2 and b3a2,
including the cases coexpressing b3a2 and b2a2, was
37.9% and 62.1%, respectively [5].
In the era of tyrosine kinase inhibitors, the impact
of the type of transcript on clinical and biological
parameters and molecular response remains
controversial. Moreover, 420 articles concerning this
topic reported that the majority of studies found no
signiﬁcant differences in terms of age, sex, leukocyte
count, and hemoglobin (Hb) level. However, in
about half of the studies, the b3a2 transcript was
associated with higher platelet counts and only a

few studies found a signiﬁcant association between
the disease risk scores and transcript types [4]. In
our series, the b3a2 transcript was signiﬁcantly more
frequent than the b2a2 transcript in women. Our
results agree with those of the large study of the
ELN registry [6]. However, in the investigation
study by Baccarani et al. [5] having concerned 180
centers in Africa, Asia, Australia, Europe, North
America, and South America, the proportion of
these two transcripts was correlated with sex, b2a2
being more frequent in men (39.2%) than in women
(36.2%; p < .0001).
No differences were found in prognostic scores.
Similar results have been found in other studies
[7e11]. By contrast, Deb et al. [12] demonstrated that
patients expressing b2a2 had higher Sokal and
EUTOS scores ( p < .05). In our study, patients
expressing b2a2 appeared to have higher mean
leukocyte count indicating greater tumor charge
than those expressing b3a2. No difference was
observed for average number of platelets or Hb
concentration. Our results were similar to other reports, which do not show a correlation between the
type of transcript and the hematological parameters,
especially the platelets count [13,14]. However, other
studies have revealed a statistically signiﬁcant
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difference. A larger study from the German group
[15] evaluated 1105 patients treated with IM and
showed that patients expressing b3a2 were characterized by a low number of white blood cell count
(65 vs. 88  109 g/L, p < 10e3) and a higher platelet
count (430 vs. 296  109 g/L, p < .001). These results,
drawn from a large cohort of patients, strongly
conﬁrm the existence of a distinct disease phenotype between b2a2 and b3a2; this may reﬂect a
different response to treatment.
Serial assays performed during the molecular
follow-up allowed us to evaluate the decrease in the
kinetics of the BCR-ABL1/ABL1 ratio and showed
that the median diagnosis rate was signiﬁcantly
higher in patients expressing b2a2 than those
expressing b3a2.
Our results conform to those obtained in the study
by Kagita et al. [11] (99.52 ± 97.25 vs. 71.32 ± 66.69;
p ¼ 0.0351).
We also found that the kinetics of reduction is
different according to the type of transcript at
different times of follow-up (12, 18, and 24 months);
however, these results were not statistical
signiﬁcant.
In our study, the most clinically relevant ﬁnding is
the association of the b3a2 fusion transcript with a
better molecular response and a shorter median
time to obtain MMR. Our results are correlated with
several published studies that suggested that in
patients expressing the b3a2 transcript, the response
to treatment is faster and deeper [4,8,10,15]. Hanfstein et al. [15] found that the cumulative probability
of achieving MMR and MR4.0 at 5 years was significantly higher in patients with b3a2 transcript (85%
vs. 81%; p ¼ .002) than in patients with b2a2 transcript (76% vs. 58%; p < .001). They also reported
that the median time to obtain MMR and MR4.0 was
also shorter in patients expressing b3a2 (14.2 vs.
18.4 months) than in those expressing b2a2 (32.4 vs.
55.2 months) [15]. Lucas et al. [8] suggested that this
may be due to patients with b2a2 having a higher
BCR-ABL tyrosine kinase activity.
In conclusion, our results suggest that the b3a2
and b2a2 transcripts may have different phenotypes,
which can have an impact on the outcome of the
disease. The b2a2 transcript appears to have a
higher tumor load and a higher tyrosine kinase activity than the b3a2 transcript. Our study ﬁndings
are in agreement with the literature data. Indeed,
we found that frontline IM-treated patients
expressing the b3a2 transcript of BCR-ABL1 presented higher rates of MMR and DMR than those
expressing the b2a2 transcript. However, these observations warrant further conﬁrmation from a
larger series. The biological mechanism responsible
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for this difference should also be investigated in
larger trials.
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